$SRNE hard to read the graphics... will post text... Highlights from SRNE’s 1Q 10Q 5/17/20 @idontbuyit 1) Cash on hand $22M. They are also selling their fully owned subsidiary, Levena Biopharma, for $30M. So effectively, they will have ~$52M in cash 2) Burn rate remains ~$12M/month 3) Company prepaid $60M of their Oaktree principal debt down 4) ZTlido sales are down q/q, but 4Q20 was an outlier (possibly due to stocking contracts) and the trend is otherwise up 5) Scilex notes were amended so that the reserve cash requirement will be reduced by 17% for the next year
  • 8